Genetic factors in chemically-induced transitional cell bladder cancer

BJU International

Volumn 86, Issue 7, 2000, Pages 794-801

  Filiadis, I ^a,b   Hrouda, D ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINE; CARCINOGEN; POLYCYCLIC AROMATIC COMPOUND;

CHEMICAL STRUCTURE; DETOXIFICATION; DNA POLYMORPHISM; HEREDITY; HUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT MALFORMATION;

ACETYLTRANSFERASES; CARCINOGENS; CARCINOMA, TRANSITIONAL CELL; GLUTATHIONE TRANSFERASE; HUMANS; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 0033767107     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00940.x     Document Type: Review

References (76)

1. World Cancer Research Fund & American Institute for Cancer Research. Cancers, nutrition and food. In American Institute for Cancer Research. Food, Nutrition and the Prevention of Cancer: a Global Perspective. 1st edn, Chapt 4.18. Washington: American Institute for Cancer Research, 1997: 338-61
2. Silverman DT, Hartge P, Morisson AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992; 6: 1-30
3. Morrison AS. Advances in the etiology of urothelial cancer. Urol Clin North Am 1984; 11: 557-66
4. Viscoli MC, Lachs M. Horwitz R. Bladder cancer and coffee drinking: a summary of case-control research. Lancet 1993; 341: 1432-7
5. Hoover RN, Strasser PH. Artificial sweeteners and human bladder cancer. Preliminary results. Lancet 1980; 1: 837-40
6. Editorial. Saccharin and bladder cancer. Lancet 1980; 1: 855-6
7. De Ridder D, van Poppel H, Demonty L et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol 1998; 159: 1881-4
8. Steffens J, Nagel R. Tumours of the renal pelvis and ureter. Observations in 170 patients. Br J Urol 1988; 61: 277-83
9. Filiadis IF, Georgiou IA, Giannakopoulos X. Urinary bladder cancer in a girl with slow-acetylator genotype and treated with sulphasalazine. Br J Urol 1998; 81: 342-3
10. Burch JD, Rohan TE, Howe GR et al. Risk of bladder cancer by source and type of tobacco exposure: a case- control study. Int J Cancer 1989; 44: 622-8
11. Rehn L. Blasengeschwuelste bei Fuchsin-Arbeitern. Arch Klin Chir 1895; 50: 588-600
12. Lower GM. Concepts in causality: chemically induced human urinary bladder cancer. Cancer 1982; 49: 1056-66
13. Wallace DMA. Occupational urothelial cancer. Br J Urol 1988; 61: 175-82
14. The British Association of Urological Surgeons (BAUS) Subcommittee on Industrial Bladder Cancer. Occupational bladder cancer: a guide for clinicians. Br J Urol 1988; 61: 183-91
15. Steineck G. Plato N, Norell SE, Hogstedt C. Urothelial Cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med 1990; 17: 571-91
16. Shields PG. Harris CC. Principles of carcinogenesis: Chemical. In DeVita VT. Hellman S, Rosenberg SA eds, Cancer; Principles and Practice of Oncology. 4th edn. Chapt 11. Philadelphia: Lippincott, 1993: 200-12
17. Boffetta P. Jourenkova N. Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997; 8: 444-72
18. Perera FP. Environment and cancer: who are susceptible? Science 1997; 278: 1068-73
19. Hail M. Grover PL. Polycyclic aromatic hydrocarbons: Metabolism, activation, and tumour initiation. In Cooper CS, Grover PL eds. Chemical Carcinogenesis and Mutayenesis. 1st edn, Berlin: Springer-Verlag, 1990: 327-72
20. Kadlubar FF. DNA adducts of carcinogenic aromatic amines. IARC Sci Pub 1994; 125: 199-216
21. Bobbins JR. Yang L-NL. Anderson BG, Falvey ED. Photogenerated arylnitrenium ions. Reactions of N-tertbutyl 1(2-acetyl 1-4-substituted) phenyl nitrenium ions with alcohols and water studied by laser flash photolysis. J Am Chem Soc 1995; 117: 6544-52
22. Weber WW, Kein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79
23. Blum M, Demiere A, Grant DM, Heim M, Meyer UA. Molecular mechanisms of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991; 88: 5237-41
24. Minchin RF. Reeves PT, Teitel CH et al. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in cos-1 cells. Biochem Biophys Res Commun 1992; 185: 839-44
25. Yu MC, Ross RK, Chan KK et al. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev 1995; 4: 861-4
26. Daly AK, Cholerton S. Armstrong M, Idlie JR. Genotype for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994; 102: 55-61
27. Weber WW. Human drug-metabolizing enzyme variants. In Roberts Frazare JA, Carter CO eds. Pharmacogenetics. Oxford Monographs on Medical Genetics. Vol 32. Oxford: Oxford University Press, 1997: 189-201
28. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann Rev Pharmacol Toxicol 1997; 37: 269-96
29. Hickman D. Risch A. Buckle V et al. Chromosomal localization of human genes for arylamine-N-acetyltransferase. Biochem J 1994; 297: 441-5
30. Bell DA. Badawi AF, Lang NP, liett KF. Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1, 10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995; 55: 5226-9
31. Hickman D, Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42: 1007-14
32. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-Acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39: 184-91
33. Weber WW. Human drug-metabolizing enzyme variants. In Roberts Frazare JA, Carter CO eds. Pharmacogenetics. Oxford Monograph on Medical Genetics. Oxford: Oxford University Press, 1997: 204-10
34. Ross VL, Board PG, Webb GC. Chromosomal mapping of the human Mu class glutathione S-transferases to Ipl3. Genomics 1993; 18: 87-91
35. Bell DA, Thompson CL, Taylor JA et al. Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase mu. Environ Health Perspect 1992; 98: 113-7
36. Pemple S, Schroeder KR, Spencer SR et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300: 271-6
37. Chen CL, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 1996; 6: 187-91
38. Harada S, Abel M, Tanaka N, Agarwal D, Goedde HW. Liver glutathione transferase polymorphism in Japanese and its pharmacogenetic importance. Hum Genet 1987; 75: 322-5
39. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988; 85: 7293-7
40. Hirvonen A. Genetic factors to individual responses to environmental exposures. J Occup Environ Med 1995; 37: 37-43
41. Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK. Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994; 15: 1077-81
42. Nelson HH, Wiencke JK, Christiani DC et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995; 16: 1243-5
43. Kempkes M. Wiebel FA, Golka K, Heitmann P. Bolt HM. Comparative genotyping and phenotyping of glutathione S-transferase GSTT1. Arch Toxicol 1996; 70: 306-9
44. Harris CC. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 1989; 10: 1563-6
45. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85: 1159-63
46. Chern HD, Romkes-Sparks M, Hu JJ et al. Homozygous deleted genotype of glutathione S-transferase Ml increases susceptibility to aggressive bladder cancer. Proc Ann Meeting Am Assoc Cancer Res 1994; 35: 285
47. Gabbani G, Hou SM, Nardini B, Marchioro M, Lambert B, Clonfero E. GSTM1 and NAT2 genotypes and urinary mutagens in coke oven workers. Carcinogenesis 1996; 17: 1677-81
48. Brockmoller J, Kerb R, Drakoulis N, Staffeldt B, Roots I. Glutathione S-transferase Ml variants A and B as host factors of bladder cancer susceptibility: a case control study. Cancer Res 1994; 54: 4103-11
49. Georgiou I, Filiadis IF, Alamanos Y, Bouba I, Giannakopoulos X, Lolis D. Glutathione-S-transferase null genotypes in transitional cell bladder cancer: a case-control study. Eur Urol 2000; 37: 660-4
50. Rothman N, Hayes RB, Zenser TV et al. The glutathione S-transferase M1 (GSTM1) null genotype and benzidine- associated bladder cancer, urine mutagenicity, and exfoliated urothelial cell DNA adducts. Cancer Epidemiol Biomarkers Prev 1996; 5: 979-83
51. Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM. Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 1996; 71: 123-6
52. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine-N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56: 3915-25
53. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursiainen K, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis 1994; 15: 813-5
54. Okkels H, Sigsgaard T, Wolf H, Autrup H. Glutathione S-transferase mu as a risk factor in bladder tumours. Pharmacogenetics 1996; 6: 251-6
55. Post U, Haillier E, Ottenwalder H, Bolt HM, Peter H. Distribution of ethylene oxide in human blood and its implications for biomonitoring. Hum Exp Toxicol 1991; 10: 25-31
56. Thier R, Foest U, Deutschmann S, Schroeder KR, Hallier E, Peter H. Distribution of methylene chloride in human blood. Arch Toxicol 1991; 14 (Suppl): 254-8
57. Wiencke JK, Pemble S, Ketterer B, Kelsey KT. Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev 1995; 4: 253-9
58. Risch A, Wallace DM, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995; 4: 231-6
59. Vineis P, Bartsch H, Caporaso H et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994; 369: 154-6
60. Filiadis IF, Georgiou I, Alamanos Y, Kranas V, Giannakopoulos X, Lolis D. Genotypes of N- acetyltransferase-2 and risk of bladder cancer: a case- control study. J Urol 1999; 161: 1672-5
61. Okkels H, Sigsgaard T. Wolf H. Autrup H. Arylamine N-acetyltransferase 1 (NAT-1) and 2 (NAT-2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 1997; 6: 225-31
62. Hietanen E, Husgafvel-Pursiainen K, Vainio H. Interaction between dose and susceptibility to environmental cancer: a short review. Environ Health Perspect 1997; 105 (Suppl 4): 749-54
63. Nakayama T, Zaman MM. Tanaka H. Reporting of attributable and relative risks. 1996-97. Lancet 1998; 351: 1179
64. Smith MT, Evans CG, Doane-Setzer P, Castro VM, Tahir MK, Mannervik B. Denitrosation of 1,3-bis (2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res 1989; 49: 2621-5
65. Miura T, Masako K, Masahiro K. A case-control study on the relationship of CYP1A1 and GSTM1 gene polymorphisms with bladder cancer patients. Br J Urol 1997; 80 (Suppl 2): 66
66. Brockmoller J. Kaiser R, Kerb R, Cascorbi I. Jaeger V, Roots I. Polymorphic enzymes of xenobiotic metabolism as modulators of acquired p53 mutations in bladder cancer. Pharmacogenetics 1996; 6: 535-45
67. Stein JP, Grossfeld GD. Ginsberg DA et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160: 645-59
68. Romkes M, Chern HD, Lesnick TG et al. Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer. Carcinogenesis 1996; 17: 1057-62
69. Kloth MT, Gee RL, Messing EM, Swaminathan S. Expression of N-acetyltransferase (NAT) in culture human uroepithelial cells. Carcinogenesis 1994; 15: 2781-7
70. McManus EM. Burgess MW, Veronese EM. Huggett A, Quattrochi CL, Tuckey HH. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food derived heterocyclic amine mutagens by human cytochromes P450. Cancer Res 1990; 50: 3367-76
71. Lee SW, Jang IJ, Shin SG et al. CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci 1994; 9: 482-9
72. Raunio H, Husgafvel-Pursiainen K. Anttila S. Hietanen E. Hirvonen A, Pelkonen O. Diagnosis of polymorphisms in carcinoma-activating and inactivating enzymes and cancer susceptibility - a review. Gene 1995; 159: 113-21
73. Kaisary A, Smith PJB, Jacqz E et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47: 5488-93
74. Fuller BP. Kahn MJE, Barr PA et al. Privacy in genetics research. Science 1999; 285: 1359-61
75. Vineis P. Schulte PA. Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype. J Clin Epidemiol 1995; 48: 189-97
76. Doll R. An epidemiological perspective of the biology of cancer. Cancer Res 1978; 38: 3573-83